{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:19Z","timestamp":1790352559394,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clml.2018.08.020","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T12:57:56Z","timestamp":1536584276000},"page":"53-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome\u00a0Negative Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"19","author":[{"given":"Ivana","family":"Horvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Boban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta Radic","family":"Antolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranka","family":"Serventi-Seiwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Roncevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Radman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Sertic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Vodanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drazen","family":"Pulanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Basic-Kinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadira","family":"Durakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Zupancic-Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Nemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Labar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.08.020_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.020_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.08.020_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2 V617F","volume":"1","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2018.08.020_bib4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.08.020_bib6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.020_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/asheducation-2005.1.201","article-title":"Management of polycythemia vera and essential thrombocythemia","volume":"2005","author":"Campbell","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.08.020_bib8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib9","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.020_bib10","first-page":"2687","article-title":"Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study","volume":"9","author":"Cascavilla","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2018.08.020_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.23676","article-title":"JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events","volume":"89","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.08.020_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2018.08.020_bib13","first-page":"345","article-title":"Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm","volume":"39","author":"Malysz","year":"2009","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.clml.2018.08.020_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ejh.12554","article-title":"Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide","volume":"96","author":"Schwarz","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.08.020_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3324\/haematol.13869","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia","volume":"94","author":"De Stefano","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.020_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00277-013-1838-6","article-title":"The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia","volume":"93","author":"Trifa","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.08.020_bib17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A\u00a0simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2018.08.020_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.020_bib19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1172\/JCI117623","article-title":"Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C","volume":"94","author":"Zoller","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.08.020_bib20","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A\u00a0common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2018.08.020_bib22","doi-asserted-by":"crossref","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.08.020_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.020_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2018.08.020_bib25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.08.020_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.020_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12032-014-0231-1","article-title":"The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2018.08.020_bib29","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.020_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.6061\/clinics\/2013(03)OA09","article-title":"Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome","volume":"68","author":"Benites","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.clml.2018.08.020_bib32","first-page":"408","article-title":"Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study","volume":"90","author":"Gisslinger","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.020_bib33","first-page":"488","article-title":"Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism","volume":"42","author":"Coen","year":"2001","journal-title":"Croat Med J"},{"key":"10.1016\/j.clml.2018.08.020_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.moh.0000190107.54790.de","article-title":"Leukocyte adhesion and thrombosis","volume":"13","author":"Afshar-Kharghan","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2018.08.020_bib35","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1055\/s-2002-36700","article-title":"Aging and thrombosis","volume":"28","author":"Wilkerson","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2018.08.020_bib37","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"CME article development and validation of an International Prognostic Score of Thrombosis in World Health Organization\u2014Essential Thrombocythemia (IPSET-Thrombosis )","volume":"120","author":"Barbui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.020_bib38","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.020_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.020_bib40","first-page":"1477","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2 V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Hematology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018310498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018310498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:14Z","timestamp":1761870734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018310498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2152265018310498"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome\u00a0Negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}